Lung cancer

Update on Cancer Therapeutics

Volumn 1, Issue 2, 2006, Pages 235-272

  Giaccone, Giuseppe ^a   Smit, Egbert ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; EGFR; Lung cancer; Mesothelioma; Non small cell lung cancer; Small cell lung cancer; Targeted therapy; Thymoma

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; DOXORUBICIN; ENOXAPARIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; MITOMYCIN C; NAVELBINE; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEMOZOLOMIDE; TOPOTECAN; UFT; UNINDEXED DRUG; VINBLASTINE; VINDESINE;

ANEMIA; ANOREXIA; ASTHENIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRONCHUS STENOSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DIAGNOSTIC IMAGING; DIARRHEA; DRUG ACTIVITY; DRUG ERUPTION; DRUG INDUSTRY; DYSGEUSIA; EPISTAXIS; ESOPHAGITIS; ESOPHAGUS STRICTURE; FATIGUE; FEBRILE NEUTROPENIA; HAIR LOSS; HEART INFARCTION; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TOXICITY; MESOTHELIOMA; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SKIN TOXICITY; SNEEZING; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; THYMOMA;

EID: 33746289901     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.05.006     Document Type: Review

References (309)

1. Hotta K., Matsuo K., Ueoka H., et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22 (2004) 3860-3867
2. Sedrakyan A., Van Der M.J., O'Byrne K., et al. Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 128 (2004) 414-419
3. Hamada C., Tanaka F., Ohta M., et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23 (2005) 4999-5006
4. Kato H., Ichinose Y., Ohta M., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721
5. Nakagawa M., Tanaka F., Tsubota N., et al. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)-the 4th study. Ann Oncol 16 (2005) 75-80
6. Imaizumi M. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer 49 (2005) 85-94
7. Ueda H., Sakada T., Kuwahara M., et al. A small randomized phase III single-center trial on postoperative UFT administration in patients with completely resected non-small cell lung cancer. Anticancer Drugs 15 (2004) 29-33
8. Dediu M., Horvat T., Tarlea A., et al. Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patients. Lung Cancer 47 (2005) 93-101
9. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
10. Waller D., Peake M.D., Stephens R.J., et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26 (2004) 173-182
11. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
12. Tada H., Tsuchiya R., Ichinose Y., et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 43 (2004) 167-173
13. Wakelee H.A., Stephenson P., Keller S.M., et al. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer 48 (2005) 389-397
14. Bradley J.D., Paulus R., Graham M.V., et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group-RTOG 9705. J Clin Oncol 23 (2005) 3480-3487
15. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update. J Clin Oncol 22 (2004) 330-353
16. Stephens R.J., Girling D.J., Hopwood P., et al. A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer. Lung Cancer 49 (2005) 395-400
17. Burkes R.L., Shepherd F.A., Blackstein M.E., et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial. Lung Cancer 47 (2005) 103-109
18. Lorent N., De Leyn P., Lievens Y., et al. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 15 (2004) 1645-1653
19. Cappuzzo F., De Marinis F., Nelli F., et al. Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally advanced non-small cell lung cancer. Lung Cancer 42 (2003) 355-361
20. De Pas T., Curigliano G., Veronesi G., et al. Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2-stage IIIb non-small-cell lung cancer: a prospective phase-II study. Bull Cancer 91 (2004) E273-E277
21. Schumacher A., Riesenbeck D., Braunheim M., et al. Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life. Lung Cancer 44 (2004) 89-97
22. Trodella L., Granone P., Valente S., et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol 15 (2004) 389-398
23. Semik M., Riesenbeck D., Linder A., et al. Preoperative chemotherapy with and without additional radiochemotherapy: benefit and risk for surgery of stage III non-small cell lung cancer. Eur J Cardiothorac Surg 26 (2004) 1205-1210
24. Sculier J.P., Lafitte J.J., Berghmans T., et al. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann Oncol 15 (2004) 399-409
25. Hainsworth J.D., Gray J.R., Litchy S., et al. A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer. Clin Lung Cancer 6 (2004) 33-42
26. Mamon H.J., Yeap B.Y., Janne P.A., et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 23 (2005) 1530-1537
27. Gaspar L.E., Chansky K., Albain K.S., et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol 23 (2005) 2955-2961
28. Fournel P., Robinet G., Thomas P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23 (2005) 5910-5917
29. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46 (2004) 87-98
30. Belani C.P., Choy H., Bonomi P., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23 (2005) 5883-5891
31. Belani C.P., Wang W., Johnson D.H., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23 (2005) 3760-3767
32. Cakir S., and Egehan I. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 43 (2004) 309-316
33. Groen H.J., van der Leest A.H., Fokkema E., et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol 15 (2004) 427-432
34. Atagi S., Kawahara M., Tamura T., et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol 35 (2005) 195-201
35. Sarihan S., Kayisogullari U., Ercan I., et al. Randomized phase 2 study of radiotherapy alone versus radiotherapy with paclitaxel in non-small cell lung cancer. J Int Med Res 32 (2004) 375-383
36. Movsas B., Scott C., Langer C., et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23 (2005) 2145-2154
37. Komaki R., Lee J.S., Milas L., et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58 (2004) 1369-1377
38. Antonadou D., Throuvalas N., Petridis A., et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 57 (2003) 402-408
39. Thongprasert S., and Chewaskulyong B. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer. J Med Assoc Thai 87 (2004) 1162-1167
40. Sekine I., Noda K., Oshita F., et al. Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Cancer Sci 95 (2004) 691-695
41. Winterhalder R., Deschler-Marini S., Landmann C., et al. Vinorelbine plus low-dose cisplatinum with concomitant radiotherapy for the treatment of locally advanced or inoperable non-metastasized non-small-cell lung cancer (stages I-IIIB): a phase II study. Radiother Oncol 73 (2004) 321-324
42. Brunsvig P.F., Hatlevoll R., Berg R., et al. Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: a phase I/II study with 5 years' follow-up. Lung Cancer 50 (2005) 97-105
43. Vergnenegre A., Daniel C., Lena H., et al. Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC). Lung Cancer 47 (2005) 395-404
44. Park J., Ahn Y.C., Kim H., et al. A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. Lung Cancer 42 (2003) 227-235
45. Argiris A., Liptay M., LaCombe M., et al. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Lung Cancer 45 (2004) 243-253
46. Divers S.G., Spencer S.A., Carey D., et al. Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 6664-6673
47. Kim Y.S., Yoon S.M., Choi E.K., et al. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 62 (2005) 76-81
48. Kaplan B., Altynbas M., Eroglu C., et al. Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC). Am J Clin Oncol 27 (2004) 603-610
49. Leong S.S., Fong K.W., Ong Y.K., et al. Chemo-radiotherapy for stage III unresectable non-small cell lung cancer long-term results of a prospective study. Respir Med 98 (2004) 1080-1086
50. Sakai H., Yoneda S., Kobayashi K., et al. Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. Lung Cancer 43 (2004) 195-201
51. Hasegawa Y., Takanashi S., Okudera K., et al. Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study. Jpn J Clin Oncol 34 (2004) 647-653
52. Ichinose Y., Nakai Y., Kudoh S., et al. Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10 (2004) 4369-4373
53. Liao Z., Komaki R., Milas L., et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11 (2005) 3342-3348
54. Schild S.E., Wong W.W., Vora S.A., et al. The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 62 (2005) 1432-1437
55. Reguart N., Vinolas N., Casas F., et al. Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results. Lung Cancer 45 (2004) 67-75
56. Ishikura S., Ohe Y., Nihei K., et al. A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 61 (2005) 1117-1122
57. Jeremic B., Milicic B., Acimovic L., et al. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study. J Clin Oncol 23 (2005) 1144-1151
58. Jeremic B., Milicic B., Acimovic L., et al. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study. J Clin Oncol 23 (2005) 6873-6880
59. Marks L.B., Garst J., Socinski M.A., et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol 22 (2004) 4329-4340
60. Socinski M.A., Morris D.E., Halle J.S., et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 22 (2004) 4341-4350
61. Chen M., Chen Y.Y., Bao Y., et al. Neoadjuvant chemotherapy followed by late-course accelerated hyperfractionated radiation therapy for locally advanced non-small-cell lung cancer: long-term results of a phase I/II clinical trial. Clin Lung Cancer 6 (2005) 304-309
62. Schwarzenberger P., Theodossiou C., Barron S., et al. Dose escalation of docetaxel concomitant with hypofractionated, once weekly chest radiotherapy for non-small-cell lung cancer: a phase I study. Am J Clin Oncol 27 (2004) 395-399
63. Pradier O., Lederer K., Hille A., et al. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter. J Cancer Res Clin Oncol 131 (2005) 261-269
64. Choy H., Nabid A., Stea B., et al. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5918-5928
65. Kommareddy A., Coplin M.A., Gao F., et al. Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience. Lung Cancer 45 (2004) 221-225
66. Argiris A., and Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 43 (2004) 317-322
67. Lee D.H., Han J.Y., Lee H.G., et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 11 (2005) 3032-3037
68. West H.L., Crowley J.J., Vance R.B., et al. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-h infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol 16 (2005) 1076-1080
69. Scagliotti G.V., Smit E., Bosquee L., et al. A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer 50 (2005) 91-96
70. Dongiovanni D., Fissore C., Berruti A., et al. Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study. Lung Cancer 47 (2005) 269-275
71. Stewart D.J., Tomiak E., Shamji F.M., et al. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer. Lung Cancer 44 (2004) 241-249
72. Marsland T.A., Garfield D.H., Khan M.M., et al. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two phase II, multicenter trials. Lung Cancer 47 (2005) 111-120
73. Spiro S.G., Rudd R.M., Souhami R.L., et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59 (2004) 828-836
74. Lilenbaum R.C., Herndon J.E., List M.A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 23 (2005) 190-196
75. Georgoulias V., Ardavanis A., Agelidou A., et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 22 (2004) 2602-2609
76. Hotta K., Matsuo K., Ueoka H., et al. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 15 (2004) 1782-1789
77. Hotta K., Matsuo K., Ueoka H., et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 3852-3859
78. Le Chevalier T., Scagliotti G., Natale R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80
79. Rudd R.M., Gower N.H., Spiro S.G., et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23 (2005) 142-153
80. Belani C.P., Lee J.S., Socinski M.A., et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 16 (2005) 1069-1075
81. Kubota K., Watanabe K., Kunitoh H., et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22 (2004) 254-261
82. Martoni A., Marino A., Sperandi F., et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 41 (2005) 81-92
83. Paccagnella A., Favaretto A., Oniga F., et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 43 (2004) 83-91
84. D'Addario G., Pintilie M., Leighl N.B., et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23 (2005) 2926-2936
85. Stathopoulos G.P., Veslemes M., Georgatou N., et al. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol 15 (2004) 1048-1055
86. Georgoulias V., Ardavanis A., Tsiafaki X., et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23 (2005) 2937-2945
87. Pujol J.L., Breton J.L., Gervais R., et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16 (2005) 602-610
88. Laack E., Dickgreber N., Muller T., et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 22 (2004) 2348-2356
89. Tan E.H., Szczesna A., Krzakowski M., et al. Randomized study of vinorelbine-gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 49 (2005) 233-240
90. Bissett D., O'Byrne K.J., von Pawel J., et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 23 (2005) 842-849
91. Behrendt C.E., and Ruiz R.B. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost 90 (2003) 734-737
92. Leighl N.B., Paz-Ares L., Douillard J.Y., et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 23 (2005) 2831-2839
93. Douillard J.Y., Peschel C., Shepherd F., et al. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 46 (2004) 361-368
94. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
95. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
96. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
97. O'Brien M.E., Anderson H., Kaukel E., et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol 15 (2004) 906-914
98. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
99. Sandler A., Gray R., Brahmer J., et al. A randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer. An Eastern Cooperative Group trial-E4599. J Clin Oncol 23 (2005) [abstract]
100. Gatzemeier U., Groth G., Butts C., et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15 (2004) 19-27
101. Ma C.X., Nair S., Thomas S., et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5929-5937
102. Guerrieri M., Wong K., Ryan G., et al. A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 46 (2004) 107-111
103. Douillard J.Y., Gervais R., Dabouis G., et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. Ann Oncol 16 (2005) 81-89
104. Lilenbaum R.C., Chen C.S., Chidiac T., et al. Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 16 (2005) 97-101
105. Chen Y.M., Perng R.P., Shih J.F., et al. A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated. Lung Cancer 47 (2005) 373-380
106. Quoix E., Breton J.L., Ducolone A., et al. First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule. Lung Cancer 47 (2005) 405-412
107. Comella P., Frasci G., Carnicelli P., et al. Gemcitabine with either paclitaxel or vinorelbine vs. paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 91 (2004) 489-497
108. Baka S., Ashcroft L., Anderson H., et al. Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status
109. Chen Y.M., Perng R.P., Shih J.F., et al. A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated. Br J Cancer 90 (2004) 359-365
110. Scagliotti G.V., Kortsik C., Dark G.G., et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 11 (2005) 690-696
111. Edelman M.J., Clark J.I., Chansky K., et al. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10 (2004) 5022-5026
112. Pathak A.K., Bhutani M., Guleria R., et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr 24 (2005) 16-21
113. Butts C., Murray N., Maksymiuk A., et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23 (2005) 6674-6681
114. Westeel V., Quoix E., Moro-Sibilot D., et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 499-506
115. Hensing T.A., Schell M.J., Lee J.H., et al. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer 47 (2005) 253-259
116. Kaneda H., Tamura K., Kurata T., et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 46 (2004) 247-254
117. Hotta K., Kiura K., Ueoka H., et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46 (2004) 255-261
118. Chiu C.H., Tsai C.M., Chen Y.M., et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47 (2005) 129-138
119. Cella D., Herbst R.S., Lynch T.J., et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 23 (2005) 2946-2954
120. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
121. Shah N.T., Kris M.G., Pao W., et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23 (2005) 165-174
122. Perez-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22 (2004) 3238-3247
123. Herbst R.S., Johnson D.H., Mininberg E., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 (2005) 2544-2555
124. Clamon G., Herndon J., Kern J., et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer 103 (2005) 1670-1675
125. Lara Jr. P.N., Laptalo L., Longmate J., et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer 5 (2004) 231-236
126. Raez L.E., Cassileth P.A., Schlesselman J.J., et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 2800-2807
127. Nemunaitis J., Sterman D., Jablons D., et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96 (2004) 326-331
128. Hirschowitz E.A., Foody T., Kryscio R., et al. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 22 (2004) 2808-2815
129. Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
130. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
131. Janne P.A., Engelman J.A., and Johnson B.E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23 (2005) 3227-3234
132. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
133. Esteban E., Gonzalez dS, Fernandez Y., et al. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 14 (2003) 1640-1647
134. Gervais R., Ducolone A., Breton J.L., et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16 (2005) 90-96
135. 2) as second-line monotherapy for non-small-cell lung cancer. Ann Oncol 15 (2004) 38-44
136. Pectasides D., Pectasides M., Farmakis D., et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 16 (2005) 294-299
137. Wachters F.M., Groen H.J., Biesma B., et al. A randomised phase II trial of docetaxel vs. docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 92 (2005) 15-20
138. Georgoulias V., Kouroussis C., Agelidou A., et al. Irinotecan plus gemcitabine vs. irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 91 (2004) 482-488
139. Yamamoto N., Fukuoka M., Negoro S.I., et al. Randomised phase II study of docetaxel/cisplatin vs. docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). Br J Cancer 90 (2004) 87-92
140. Singh S., Parulekar W., Murray N., et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 23 (2005) 850-856
141. Kamel E.M., Zwahlen D., Wyss M.T., et al. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 44 (2003) 1911-1917
142. Bradley J.D., Dehdashti F., Mintun M.A., et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 22 (2004) 3248-3254
143. Brink I., Schumacher T., Mix M., et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 31 (2004) 1614-1620
144. Fried D.B., Morris D.E., Poole C., et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22 (2004) 4837-4845
145. Turrisi III A.T., Kim K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (1999) 265-271
146. Schild S.E., Bonner J.A., Shanahan T.G., et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 59 (2004) 943-951
147. Schild S.E., Stella P.J., Brooks B.J., et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer 103 (2005) 2349-2354
148. Komaki R., Swann R.S., Ettinger D.S., et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 62 (2005) 342-350
149. Lee S.H., Ahn Y.C., Kim H.J., et al. Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer. Jpn J Clin Oncol 33 (2003) 620-625
150. Edelman M.J., Chansky K., Gaspar L.E., et al. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. J Clin Oncol 22 (2004) 127-132
151. Le Q.T., McCoy J., Williamson S., et al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res 10 (2004) 5418-5424
152. Ettinger D.S., Berkey B.A., Abrams R.A., et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 23 (2005) 4991-4998
153. Han J.Y., Cho K.H., Lee D.H., et al. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol 23 (2005) 3488-3494
154. Giaccone G., Debruyne C., Felip E., et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 23 (2005) 6854-6864
155. Lorigan P., Woll P.J., O'Brien M.E., et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 97 (2005) 666-674
156. Ardizzoni A., Favaretto A., Boni L., et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis-a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 23 (2005) 569-575
157. Noda K., Nishiwaki Y., Kawahara M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2002) 85-91
158. Seifart U., Jensen K., Ukena J., et al. Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung Cancer 48 (2005) 415-422
159. Niell H.B., Herndon J.E., Miller A.A., et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23 (2005) 3752-3759
160. De Marinis F., Nelli F., Lombardo M., et al. A multicenter, randomized, phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma. Cancer 103 (2005) 772-779
161. Artel-Cortes A., Gomez-Codina J., Gonzalez-Larriba J.L., et al. Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. Clin Lung Cancer 6 (2004) 175-183
162. Ohe Y., Negoro S., Matsui K., et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 16 (2005) 430-436
163. Neubauer M., Heaven R., Olivares J., et al. Results of a phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer. Lung Cancer 46 (2004) 369-375
164. Schmittel A., Schulze K., Hutter G., et al. Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer. Onkologie 27 (2004) 280-284
165. Felip E., Rosell R., Domine M., et al. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. Ann Oncol 14 (2003) 1549-1554
166. Perez E.A., Geoffroy F.J., Hillman S., et al. Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Lung Cancer 44 (2004) 347-353
167. Reck M., Groth G., Buchholz E., et al. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Lung Cancer 48 (2005) 409-413
168. Ando M., Kobayashi K., Yoshimura A., et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 44 (2004) 121-127
169. Goto K., Sekine I., Nishiwaki Y., et al. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer 91 (2004) 659-665
170. Agelaki S., Syrigos K., Christophylakis C., et al. A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Oncology 66 (2004) 192-196
171. Dudek A.Z., Lesniewski-Kmak K., Bliss R.L., et al. Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer. Lung 183 (2005) 43-52
172. Agelaki S., Veslemes M., Syrigos K., et al. A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. Lung Cancer 43 (2004) 329-333
173. Johnson B.E., Fischer T., Fischer B., et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9 (2003) 5880-5887
174. Krug L.M., Crapanzano J.P., Azzoli C.G., et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 103 10 (2005) 2128-2131
175. Heymach J.V., Johnson D.H., Khuri F.R., et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 15 (2004) 1187-1193
176. Punt C.J., de Jonge M.J., Monfardini S., et al. RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group. Eur J Cancer 40 (2004) 1332-1334
177. Rudin C.M., Kozloff M., Hoffman P.C., et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22 (2004) 1110-1117
178. Krug L.M., Ragupathi G., Ng K.K., et al. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10 (2004) 916-923
179. Krug L.M., Ragupathi G., Hood C., et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10 (2004) 6094-6100
180. Harper-Wynne C.L., Sumpter K., Ryan C., et al. Addition of SRL 172 to standard chemotherapy in small cell lung cancer (SCLC) improves symptom control. Lung Cancer 47 (2005) 289-290
181. Muers M.F., Rudd R.M., O'Brien M.E., et al. BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax 59 (2004) 144-148
182. van Meerbeeck J.P., Gaafar R., Manegold C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 (2005) 6881-6889
183. Weder W., Kestenholz P., Taverna C., et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22 (2004) 3451-3457
184. Andreopoulou E., Ross P.J., O'Brien M.E., et al. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 15 (2004) 1406-1412
185. Fennell D.A., C Steele J.P., Shamash J., et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 47 2 (2005) 277-281
186. Portalone L., Antilli A., Nunziati F., et al. Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma. Tumori 91 (2005) 15-18
187. Otterson G.A., Herndon J.E., Watson D., et al. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer 44 (2004) 251-259
188. Kindler H.L., Herndon J.E., Zhang C., et al. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 48 (2005) 423-428
189. Belani C.P., Adak S., Aisner S., et al. Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group. Clin Lung Cancer 6 (2004) 43-47
190. Lu C., Perez-Soler R., Piperdi B., et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol 23 (2005) 3495-3501
191. Manegold C., Symanowski J., Gatzemeier U., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16 (2005) 923-927
192. Porta C., Zimatore M., Bonomi L., et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 48 (2005) 429-434
193. Govindan R., Kratzke R.A., Herndon J.E., et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11 (2005) 2300-2304
194. Baas P., Boogerd W., Dalesio O., et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48 (2005) 291-296
195. Kim E.S., Putnam J.B., Komaki R., et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 44 (2004) 369-379
196. Loehrer Sr. P.J., Wang W., Johnson D.H., et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 22 (2004) 293-299
197. Tibaldi C., Ricci S., Russo F., et al. Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO). Lung Cancer 48 (2005) 121-127
198. Ferrigno D., and Buccheri G. Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC). Lung Cancer 45 (2004) 373-380
199. Levitt M.L., Kassem B., Gooding W.E., et al. Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms. Lung Cancer 43 (2004) 335-344
200. Gridelli C., Manegold C., Mali P., et al. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur J Cancer 40 (2004) 2424-2431
201. Kanard A., Jatoi A., Castillo R., et al. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer 43 (2004) 345-353
202. Sorraritchingchai S., Thongprasert S., Charoentum C., et al. Treatment of advanced non-small cell lung cancer with vinorelbine in elderly Thai patients. J Med Assoc Thai 87 (2004) 367-371
203. Hirsh V., Latreille J., Kreisman H., et al. Sequential therapy with vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities-a multicenter phase II trial. Lung Cancer 49 (2005) 117-123
204. Baka S., Ranson M., Lorigan P., et al. A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. Eur J Cancer 41 (2005) 1547-1550
205. Takigawa N., Segawa Y., Kishino D., et al. Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients. Cancer Chemother Pharmacol 54 (2004) 230-236
206. Kommareddy A., Coplin M.A., Gao F., et al. Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience. Lung Cancer 45 (2004) 221-225
207. Lena M.D., Ramlau R., Hansen O., et al. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer 48 (2005) 129-135
208. Mori K., Kamiyama Y., Kondo T., et al. Phase II study of the combination of vinorelbine and cisplatin in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 53 (2004) 129-132
209. Jassem J., Kosmidis P., Ramlau R., et al. Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann Oncol 14 (2003) 1634-1639
210. Pereira J.R., Martins S.J., Nikaedo S.M., et al. Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) BMC. Cancer 4 (2004) 69
211. Tartarone A., Romano G., Iodice G., et al. Cisplatin and weekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer a phase II study. Tumori 91 (2005) 131-134
212. Ohe Y., Niho S., Kakinuma R., et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 15 (2004) 45-50
213. Tsunoda T., Koizumi T., Hayasaka M., et al. Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 54 (2004) 173-177
214. Mori K., Kamiyama Y., Kondo T., et al. A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer. Chemotherapy 51 (2005) 120-125
215. Kaira K., Takise A., Minato K., et al. Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. Anticancer Drugs 16 (2005) 455-460
216. Watanabe H., Yamamoto N., Tamura T., et al. Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 33 (2003) 626-630
217. Yoshimura N., Kudoh S., Mukohara T., et al. Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer. Br J Cancer 90 (2004) 1184-1189
218. Ostoros G., Szondy K., Gergely-Farnos E., et al. Efficacy of gemcitabine-cisplatin treatment in stage IIIA ("bulky"N2), IIIB and IV non-small cell lung cancer. Anticancer Res 25 (2005) 471-475
219. Ichinose Y., Yoshimori K., Sakai H., et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10 (2004) 7860-7864
220. Grossi F., Belvedere O., Fasola G., et al. Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer 46 (2004) 99-106
221. Rixe O., Gatineau M., Jauffret E., et al. Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Bull Cancer 92 (2005) E1-E6
222. Hirabayashi M., Endoh K., Teramachi M., et al. Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study. Lung Cancer 44 (2004) 355-362
223. Okamoto I., Moriyama E., Fujii S., et al. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 35 (2005) 188-194
224. de Jonge M.E., van den Bongard H.J., Huitema A.D., et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 10 (2004) 2237-2244
225. Fabi A., Barduagni M., Ferraresi V., et al. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. J Exp Clin Cancer Res 23 (2004) 25-32
226. Jatoi A., Stella P.J., Hillman S., et al. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (> or =65 years of age): a phase II North Central Cancer Treatment Group study. Am J Clin Oncol 26 (2003) 441-447
227. Kikuchi J., Yamazaki K., Kinoshita I., et al. Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer. Jpn J Clin Oncol 34 (2004) 505-509
228. Ramalingam S., Dobbs T.W., Einzig A.I., et al. Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study. Cancer Chemother Pharmacol 53 (2004) 439-444
229. Jahanzeb M., Sarna G., Hirsch R., et al. Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a phase II study. Anticancer Res 24 (2004) 1239-1242
230. Ando M., Saka H., Ando Y., et al. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences. Cancer Chemother Pharmacol 55 (2005) 552-558
231. Fukuda M., Oka M., Soda H., et al. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. Cancer Chemother Pharmacol 54 (2004) 573-577
232. O'Brien M.E., Szczesna A., Karnicka H., et al. Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study. Ann Oncol 15 (2004) 921-927
233. Mott F.E., Cable C.T., and Sharma N. Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer. Clin Lung Cancer 5 (2003) 174-176
234. Maestu I., Gomez-Aldaravi L., Torregrosa M.D., et al. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 42 (2003) 345-354
235. Tassinari D., Fochessati F., Arcangeli V., et al. Carboplatin and gemcitabine in the palliative treatment of stage IV non-small cell lung cancer: definitive results of a phase II trial. Tumori 90 (2004) 54-59
236. Chiappori A., Simon G., Williams C., et al. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology 68 (2005) 382-390
237. Cappuzzo F., Novello S., De Marinis F., et al. Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer 93 (2005) 29-34
238. Winegarden J.D., Mauer A.M., Otterson G.A., et al. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 15 (2004) 915-920
239. Yamada K., Ikehara M., Tanaka G., et al. Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807). Oncology 66 (2004) 94-100
240. Nogami N., Harita S., Ueoka H., et al. Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer. Lung Cancer 45 (2004) 85-91
241. Ziotopoulos P., Androulakis N., Mylonaki E., et al. Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study. Lung Cancer 50 (2005) 115-122
242. Ibrahim T., Zoli W., Frassineti G.L., et al. Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study. Lung Cancer 47 (2005) 261-267
243. De Castro J., Lorenzo A., Morales S., et al. Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma. Cancer Chemother Pharmacol 55 (2005) 197-202
244. Neubauer M.A., Garfield D.H., Kuerfler P.R., et al. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Lung Cancer 47 (2005) 121-127
245. Hirsh V., Whittom R., Desjardins P., et al. Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial. Lung Cancer 46 (2004) 113-118
246. Matsui K., Hirashima T., Nitta T., et al. A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer. Jpn J Clin Oncol 35 (2005) 181-187
247. Israel V., Tagawa S.T., Snyder T., et al. Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC). Invest New Drugs 22 (2004) 291-297
248. Aguiar D., Aguiar J., and Bohn U. Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 55 (2005) 152-158
249. Gillenwater H.H., Stinchcombe T.E., Qaqish B.F., et al. A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer. Lung Cancer 47 (2005) 413-419
250. Recchia F., Saggio G., Cesta A., et al. Paclitaxel plus gemcitabine in advanced non-small cell lung cancer patients with low performance status. Anticancer Res 25 (2005) 409-414
251. Yang C.H., Chen M.C., Cheng A.L., et al. Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment. Oncology 68 (2005) 350-355
252. Monnerat C., Le Chevalier T., Kelly K., et al. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 10 (2004) 5439-5446
253. Clarke S.J., Boyer M.J., Millward M., et al. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 49 (2005) 401-412
254. Katakami N., Sugiura T., Nogami T., et al. Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. Lung Cancer 43 (2004) 93-100
255. Zinner R.G., Glisson B.S., Fossella F.V., et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 44 (2004) 99-110
256. Monnerat C., Henriksson R., Le Chevalier T., et al. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 15 (2004) 316-323
257. Villalona-Calero M.A., Ritch P., Figueroa J.A., et al. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 10 (2004) 6086-6093
258. Gatineau M., Rixe O., and Chevalier T.L. Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: a phase I/II study. Clin Lung Cancer 6 (2005) 293-298
259. Edelman M.J., Smith R., Hausner P., et al. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5774-5778
260. Goffin J.R., Anderson I.C., Supko J.G., et al. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 11 (2005) 3417-3424
261. Patlakas G., Bouros D., Tsantekidou-Pozova S., et al. Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer. Anticancer Res 25 (2005) 1427-1431
262. Schmittel A., Siehl J.M., Schulze M., et al. Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients. Anticancer Res 25 (2005) 1333-1336
263. Bourgeois H., Billiart I., Chabrun V., et al. Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma. Am J Clin Oncol 27 (2004) 89-95
264. Cortes J., Rodriguez J., Calvo E., et al. Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer. Am J Clin Oncol 27 (2004) 299-303
265. Mok T.S., Lam K.C., Lee C., et al. Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer. Oncology 68 (2005) 485-492
266. Rocha Lima C.M., Rizvi N.A., Zhang C., et al. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann Oncol 15 (2004) 410-418
267. Baka S., Ashcroft L., Anderson H., et al. Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status
268. Janne P.A., Gurubhagavatula S., Yeap B.Y., et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 44 (2004) 221-230
269. Ceresoli G.L., Cappuzzo F., Gregorc V., et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15 (2004) 1042-1047
270. Santoro A., Cavina R., Latteri F., et al. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Ann Oncol 15 (2004) 33-37
271. Simon G.R., Ruckdeschel J.C., Williams C., et al. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control 10 (2003) 388-395
272. Schutte W., Nagel S., Schaedlich S., et al. Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program. Onkologie 28 (2005) 195-198
273. Cappuzzo F., Bartolini S., Ceresoli G.L., et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer 90 (2004) 82-86
274. Haringhuizen A., van Tinteren H., Vaessen H.F., et al. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Ann Oncol 15 (2004) 786-792
275. Mu X.L., Li L.Y., Zhang X.T., et al. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC. Cancer 4 (2004) 51
276. Rinehart J., Adjei A.A., Lorusso P.M., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22 (2004) 4456-4462
277. Cheng J.D., Babb J.S., Langer C., et al. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. J Clin Oncol 22 (2004) 602-609
278. Reid T., Valone F., Lipera W., et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45 (2004) 381-386
279. Miller A.A., Herndon J.E., Gu L., et al. Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). Lung Cancer 48 (2005) 399-407
280. Sherman C.A., Herndon J.E., Watson D.M., et al. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung Cancer 45 (2004) 387-392
281. Ceresoli G.L., Gregorc V., Cordio S., et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. Lung Cancer 44 (2004) 231-239
282. Yasuda K., Igishi T., Kawasaki Y., et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. Oncology 66 (2004) 347-352
283. Buccheri G., and Ferrigno D. Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin. Lung Cancer 45 (2004) 227-236
284. Rossi D., Graziano F., Ugolini M., et al. Weekly docetaxel as second-line therapy in non-small cell lung cancer: a phase II study. Tumori 90 (2004) 50-53
285. Serke M., Schoenfeld N., and Loddenkemper R. Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial. Anticancer Res 24 (2004) 1211-1216
286. Vazquez S., Grande C., Amenedo M., et al. Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00). Anticancer Drugs 15 (2004) 489-494
287. Lara Jr. P.N., Gumerlock P.H., Mack P.C., et al. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer 6 (2004) 102-107
288. Chen Y.M., Tsai C.M., and Perng R.P. Clinical experience with single-agent gemcitabine chemotherapy in patients with non-small-cell lung cancer in whom previous chemotherapy has failed. J Chin Med Assoc 68 (2005) 163-166
289. Camps C., Felip E., Sanchez J.M., et al. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol 16 (2005) 597-601
290. Giaccone G., Smit E.F., de Jonge M., et al. Glufosfamide administered by 1-h infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. Eur J Cancer 40 (2004) 667-672
291. Ando S., Suzuki M., Iida T., et al. Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer. Oncol Rep 14 (2005) 689-694
292. Park Y.H., Lee J.C., Kim C.H., et al. Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum. Jpn J Clin Oncol 34 (2004) 245-249
293. Nelli F., Naso G., De Pasquale C.A., et al. Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial. J Chemother 16 (2004) 392-399
294. Hotta K., Takigawa N., Kiura K., et al. Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Anticancer Res 25 (2005) 2429-2434
295. Nugent F.W., Mertens W.C., Graziano S., et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer 48 (2005) 267-273
296. Font A., Sanchez J.M., Taron M., et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 21 (2003) 435-443
297. Kindwall-Keller T., Otterson G.A., Young D., et al. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin Cancer Res 11 (2005) 1870-1876
298. Han J.Y., Lee D.H., Kim H.Y., et al. A phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. Clin Cancer Res 9 (2003) 5909-5914
299. Numico G., Colantonio I., Gasco M., et al. Carboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy. Anticancer Res 25 (2005) 2555-2559
300. Wachters F.M., van Putten J.W., Boezen H.M., et al. Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC. Lung Cancer 45 (2004) 255-262
301. Seto T., Takezako Y., Nakamura H., et al. Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study. Int J Clin Oncol 9 (2004) 378-382
302. Nishio M., Ohyanagi F., Taguch F., et al. Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer. Lung Cancer 48 (2005) 115-119
303. Agelaki S., Syrigos K., Christophylakis C., et al. A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Oncology 66 (2004) 192-196
304. Tas F., Demir C., Camlica H., et al. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial. Med Oncol 21 (2004) 233-240
305. Dongiovanni V., Addeo A., Berruti A., et al. A phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbine. Anticancer Res 24 (2004) 2567-2572
306. Koizumi T., Yoshiike F., Inou H., et al. Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Med Oncol 21 (2004) 133-137
307. Bidoli P., Stani S.C., Mariani L., et al. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer. Lung Cancer 43 (2004) 203-208
308. Kurata T., Tamura K., Yamamoto N., et al. Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. Br J Cancer 90 (2004) 2092-2096
309. Kim E.S., Kies M.S., Fossella F.V., et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 104 (2005) 561-569